Status:
COMPLETED
Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults
Lead Sponsor:
GlaxoSmithKline
Conditions:
Infections, Papillomavirus
Eligibility:
FEMALE
20-30 years
Phase:
PHASE2
Brief Summary
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can in...
Eligibility Criteria
Inclusion
- Participated in study 580299/001 and received all three doses of vaccine/placebo.
- Written informed consent obtained from the subject prior to enrollment
Exclusion
- Decoding of the subject's treatment allocation to either the subject or the investigator in study 580299/001.
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
776 Patients enrolled
Trial Details
Trial ID
NCT00120848
Start Date
November 1 2003
End Date
July 1 2007
Last Update
November 4 2016
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
San Francisco, California, United States, 94110
2
GSK Investigational Site
San Francisco, California, United States, 94143-0503
3
GSK Investigational Site
Augusta, Georgia, United States, 30912-3500
4
GSK Investigational Site
Bardstown, Kentucky, United States, 40004